Abvance Therapeutics
PrivateLast Round
Seed
Jun 24, 2025
Total Funding Raised
$3.9M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Abvance Therapeutics operates in Healthcare & Life Sciences and is based in Reno, Nevada. Its latest recorded funding round was a Seed round in June 2025.
Abvance Therapeutics is a biotechnology company developing glucagon-based therapies designed to prevent hypoglycemia and improve glucose management for diabetes patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Abvance Therapeutics Comparables
Compare Abvance Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Zucara Therapeutics Inc. | 78% | |
| Sensulin | 78% | |
| Zealand Pharma | 71% |
For institutional investors. Book with your work email.
Abvance Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jun 24, 2025 | ||||
| Debt | Sep 10, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Abvance Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Helmsley Charitable Trust | Debt |
| Zubi Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 93% MoM.
- Jul 28, 2026
Monthly visitors increased 55% MoM.
For institutional investors. Book with your work email.
Abvance Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Abvance Therapeutics's valuation, stock price, and market status.
Is Abvance Therapeutics a public or private company?
Abvance Therapeutics is a private company.
What is the current stock price of Abvance Therapeutics?
Abvance Therapeutics is a private company, so its shares have no public market price. Caplight tracks Abvance Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Abvance Therapeutics worth (valuation)?
Valuation information for Abvance Therapeutics is not publicly available.
Can I buy Abvance Therapeutics stock?
Abvance Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Abvance Therapeutics's last funding round?
Abvance Therapeutics's most recent funding round was Seed on June 24, 2025.
Who are the main investors in Abvance Therapeutics?
Key investors in Abvance Therapeutics include Zubi Capital.
Will Abvance Therapeutics IPO soon?
No public IPO plans have been announced for Abvance Therapeutics.
How can I track Abvance Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Abvance Therapeutics's shares on secondary markets.